Orbital Therapeutics

Orbital Therapeutics was a Cambridge, Massachusetts biotechnology company developing next-generation RNA medicines, combining circular and linear RNA, targeted delivery, and AI-guided design across immunomodulation, in vivo CAR-T cell therapy, next-generation vaccines, and protein therapeutics. Its lead program, OTX-201, targeted autoimmune disease through B-cell depletion. Founded out of Beam Therapeutics and backed by ARCH Venture Partners, a16z Bio + Health, and Newpath Partners, the company raised a $270M Series A in 2023. In October 2025 Bristol Myers Squibb agreed to acquire Orbital Therapeutics for $1.5 billion; orbitaltx.com now redirects to bms.com. As a therapeutics developer, Orbital publishes no public developer platform, API, or machine-readable API surface, so this record is an identity-only profile in the API Evangelist network.

Orbital Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, RNA Medicines, and Cell Therapy.

🌐 Visit website 📡 Source on GitHub

5.7/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5

0 APIs

CompanyBiotechnologyPharmaceuticalsRNA MedicinesCell TherapyLife SciencesCAR-TVaccines

Kin Score

Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5

Composite quality — 5.7/100 · minimal

Contract Quality 0.0 / 25

Developer Ergonomics 0.0 / 20

Commercial Clarity 0.0 / 20

Operational Transparency 0.0 / 13

Governance 0.0 / 12

Discoverability 6.8 / 10

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 15

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/orbital-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Resources

Operate 1

Status, limits, changes, and where to get help

PressRelease

PressRelease

Company 1

The organization behind the API

Website

Website

Source (apis.yml)

aid: orbital-therapeutics
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/orbital-therapeutics.png
name: Orbital Therapeutics
description: Orbital Therapeutics was a Cambridge, Massachusetts biotechnology company developing next-generation RNA medicines,
  combining circular and linear RNA, targeted delivery, and AI-guided design across immunomodulation, in vivo CAR-T cell therapy,
  next-generation vaccines, and protein therapeutics. Its lead program, OTX-201, targeted autoimmune disease through B-cell
  depletion. Founded out of Beam Therapeutics and backed by ARCH Venture Partners, a16z Bio + Health, and Newpath Partners,
  the company raised a $270M Series A in 2023. In October 2025 Bristol Myers Squibb agreed to acquire Orbital Therapeutics
  for $1.5 billion; orbitaltx.com now redirects to bms.com. As a therapeutics developer, Orbital publishes no public developer
  platform, API, or machine-readable API surface, so this record is an identity-only profile in the API Evangelist network.
url: https://raw.githubusercontent.com/api-evangelist/orbital-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- a16z
x-tier: stub
x-tier-reason: portfolio-lead
x-status: acquired
x-acquired-by: Bristol Myers Squibb
x-acquired-announced: '2025-10-10'
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-20'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- RNA Medicines
- Cell Therapy
- Life Sciences
- CAR-T
- Vaccines
apis: []
common:
- type: Website
  url: https://www.orbitaltx.com/
- type: PressRelease
  name: BMS to Acquire Orbital Therapeutics
  url: https://news.bms.com/news/details/2025/Bristol-Myers-Squibb-Strengthens-and-Diversifies-Cell-Therapy-Portfolio-with-Acquisition-of-Orbital-Therapeutics/default.aspx
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-20'
  status: minimal
  artifacts_added: 0
  pass: local-v1